Novavax expects to make available at least 2 bln COVID-19 vaccine doses in 2022

Vaccine developer Novavax Inc said on Friday at least 2 billion doses of its COVID-19 vaccine would be available in 2022.

The company, which in June announced its vaccine was more than 90% effective in a late-stage U.S.-based clinical trial, said it was on track to file an application for emergency use of its vaccine to the U.S. Food and Drug Administration in the fourth quarter.